Selected research
Industry Research
Plasmid DNA CDMO Service Industry Research Report 2026
Market perspective
The global Plasmid DNA CDMO Service market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Plasmid DNA CDMO Service market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Plasmid DNA CDMO Service market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Plasmid DNA CDMO Service market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Plasmid DNA CDMO Service include Creative Biogene, AGC Biologics, Biovian, GenScript ProBio, Charles River Laboratories, PackGene, Catalent Biologics, Patheon and Mycenax Biotech Inc, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Plasmid DNA CDMO Service market in terms of revenue (US$ million) and, where applicable, service volume (k units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/k units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Plasmid DNA CDMO Service.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Plasmid DNA CDMO Service Market by Company
Creative Biogene
AGC Biologics
Biovian
GenScript ProBio
Charles River Laboratories
PackGene
Catalent Biologics
Patheon
Mycenax Biotech Inc
VGXI
Esco Aster
Eurogentec
53Biologics
SK pharmteco
Cytovance Biologics
Aldevron
Bionova Scientific
Plasmid DNA CDMO Service Segment by Type
Research Grade
Commercial Grade
GMP Grade
Others
Plasmid DNA CDMO Service Segment by Application
Preclinical
Clinical
Commercial
Plasmid DNA CDMO Service Segment by Region
North America
United States
Canada
Mexico
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
Taiwan
Southeast Asia
South America
Brazil
Argentina
Chile
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Plasmid DNA CDMO Service market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Plasmid DNA CDMO Service and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Plasmid DNA CDMO Service.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Plasmid DNA CDMO Service companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- Research Grade
- Commercial Grade
- GMP Grade
- Others
Applications
- Preclinical
- Clinical
- Commercial
Companies covered
- Creative Biogene
- AGC Biologics
- Biovian
- GenScript ProBio
- Charles River Laboratories
- PackGene
- Catalent Biologics
- Patheon
- Mycenax Biotech Inc
- VGXI
- Esco Aster
- Eurogentec
- 53Biologics
- SK pharmteco
- Cytovance Biologics
- Aldevron
- Bionova Scientific
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Plasmid DNA CDMO Service by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 Research Grade
- 2.2.3 Commercial Grade
- 2.2.4 GMP Grade
- 2.2.5 Others
- 2.3 Plasmid DNA CDMO Service by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Preclinical
- 2.3.3 Clinical
- 2.3.4 Commercial
- 2.4 Assumptions and Limitations
3 Plasmid DNA CDMO Service Breakdown Data by Type
- 3.1 Global Plasmid DNA CDMO Service Historic Market Size by Type (2021-2026)
- 3.2 Global Plasmid DNA CDMO Service Forecasted Market Size by Type (2027-2032)
4 Plasmid DNA CDMO Service Breakdown Data by Application
- 4.1 Global Plasmid DNA CDMO Service Historic Market Size by Application (2021-2026)
- 4.2 Global Plasmid DNA CDMO Service Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Plasmid DNA CDMO Service Market Perspective (2021-2032)
- 5.2 Global Plasmid DNA CDMO Service Growth Trends by Region
- 5.2.1 Global Plasmid DNA CDMO Service Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Plasmid DNA CDMO Service Historic Market Size by Region (2021-2026)
- 5.2.3 Plasmid DNA CDMO Service Forecasted Market Size by Region (2027-2032)
- 5.3 Plasmid DNA CDMO Service Market Dynamics
- 5.3.1 Plasmid DNA CDMO Service Industry Trends
- 5.3.2 Plasmid DNA CDMO Service Market Drivers
- 5.3.3 Plasmid DNA CDMO Service Market Challenges
- 5.3.4 Plasmid DNA CDMO Service Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Plasmid DNA CDMO Service Players by Revenue
- 6.1.1 Global Top Plasmid DNA CDMO Service Players by Revenue (2021-2026)
- 6.1.2 Global Plasmid DNA CDMO Service Revenue Market Share by Players (2021-2026)
- 6.2 Global Plasmid DNA CDMO Service Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Plasmid DNA CDMO Service Head Office and Area Served
- 6.4 Global Plasmid DNA CDMO Service Players, Product Type & Application
- 6.5 Global Plasmid DNA CDMO Service Manufacturers Established Date
- 6.6 Global Plasmid DNA CDMO Service Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Plasmid DNA CDMO Service Market Size (2021-2032)
- 7.2 North America Plasmid DNA CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Plasmid DNA CDMO Service Market Size by Country (2021-2026)
- 7.4 North America Plasmid DNA CDMO Service Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Plasmid DNA CDMO Service Market Size (2021-2032)
- 8.2 Europe Plasmid DNA CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Plasmid DNA CDMO Service Market Size by Country (2021-2026)
- 8.4 Europe Plasmid DNA CDMO Service Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Plasmid DNA CDMO Service Market Size (2021-2032)
- 9.2 Asia-Pacific Plasmid DNA CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Plasmid DNA CDMO Service Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Plasmid DNA CDMO Service Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Plasmid DNA CDMO Service Market Size (2021-2032)
- 10.2 South America Plasmid DNA CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Plasmid DNA CDMO Service Market Size by Country (2021-2026)
- 10.4 South America Plasmid DNA CDMO Service Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Plasmid DNA CDMO Service Market Size (2021-2032)
- 11.2 Middle East & Africa Plasmid DNA CDMO Service Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Plasmid DNA CDMO Service Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Plasmid DNA CDMO Service Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Creative Biogene
- 12.1.1 Creative Biogene Company Information
- 12.1.2 Creative Biogene Business Overview
- 12.1.3 Creative Biogene Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.1.4 Creative Biogene Plasmid DNA CDMO Service Product Portfolio
- 12.1.5 Creative Biogene Recent Developments
- 12.2 AGC Biologics
- 12.2.1 AGC Biologics Company Information
- 12.2.2 AGC Biologics Business Overview
- 12.2.3 AGC Biologics Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.2.4 AGC Biologics Plasmid DNA CDMO Service Product Portfolio
- 12.2.5 AGC Biologics Recent Developments
- 12.3 Biovian
- 12.3.1 Biovian Company Information
- 12.3.2 Biovian Business Overview
- 12.3.3 Biovian Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.3.4 Biovian Plasmid DNA CDMO Service Product Portfolio
- 12.3.5 Biovian Recent Developments
- 12.4 GenScript ProBio
- 12.4.1 GenScript ProBio Company Information
- 12.4.2 GenScript ProBio Business Overview
- 12.4.3 GenScript ProBio Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.4.4 GenScript ProBio Plasmid DNA CDMO Service Product Portfolio
- 12.4.5 GenScript ProBio Recent Developments
- 12.5 Charles River Laboratories
- 12.5.1 Charles River Laboratories Company Information
- 12.5.2 Charles River Laboratories Business Overview
- 12.5.3 Charles River Laboratories Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.5.4 Charles River Laboratories Plasmid DNA CDMO Service Product Portfolio
- 12.5.5 Charles River Laboratories Recent Developments
- 12.6 PackGene
- 12.6.1 PackGene Company Information
- 12.6.2 PackGene Business Overview
- 12.6.3 PackGene Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.6.4 PackGene Plasmid DNA CDMO Service Product Portfolio
- 12.6.5 PackGene Recent Developments
- 12.7 Catalent Biologics
- 12.7.1 Catalent Biologics Company Information
- 12.7.2 Catalent Biologics Business Overview
- 12.7.3 Catalent Biologics Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.7.4 Catalent Biologics Plasmid DNA CDMO Service Product Portfolio
- 12.7.5 Catalent Biologics Recent Developments
- 12.8 Patheon
- 12.8.1 Patheon Company Information
- 12.8.2 Patheon Business Overview
- 12.8.3 Patheon Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.8.4 Patheon Plasmid DNA CDMO Service Product Portfolio
- 12.8.5 Patheon Recent Developments
- 12.9 Mycenax Biotech Inc
- 12.9.1 Mycenax Biotech Inc Company Information
- 12.9.2 Mycenax Biotech Inc Business Overview
- 12.9.3 Mycenax Biotech Inc Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.9.4 Mycenax Biotech Inc Plasmid DNA CDMO Service Product Portfolio
- 12.9.5 Mycenax Biotech Inc Recent Developments
- 12.10 VGXI
- 12.10.1 VGXI Company Information
- 12.10.2 VGXI Business Overview
- 12.10.3 VGXI Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.10.4 VGXI Plasmid DNA CDMO Service Product Portfolio
- 12.10.5 VGXI Recent Developments
- 12.11 Esco Aster
- 12.11.1 Esco Aster Company Information
- 12.11.2 Esco Aster Business Overview
- 12.11.3 Esco Aster Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.11.4 Esco Aster Plasmid DNA CDMO Service Product Portfolio
- 12.11.5 Esco Aster Recent Developments
- 12.12 Eurogentec
- 12.12.1 Eurogentec Company Information
- 12.12.2 Eurogentec Business Overview
- 12.12.3 Eurogentec Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.12.4 Eurogentec Plasmid DNA CDMO Service Product Portfolio
- 12.12.5 Eurogentec Recent Developments
- 12.13 53Biologics
- 12.13.1 53Biologics Company Information
- 12.13.2 53Biologics Business Overview
- 12.13.3 53Biologics Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.13.4 53Biologics Plasmid DNA CDMO Service Product Portfolio
- 12.13.5 53Biologics Recent Developments
- 12.14 SK pharmteco
- 12.14.1 SK pharmteco Company Information
- 12.14.2 SK pharmteco Business Overview
- 12.14.3 SK pharmteco Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.14.4 SK pharmteco Plasmid DNA CDMO Service Product Portfolio
- 12.14.5 SK pharmteco Recent Developments
- 12.15 Cytovance Biologics
- 12.15.1 Cytovance Biologics Company Information
- 12.15.2 Cytovance Biologics Business Overview
- 12.15.3 Cytovance Biologics Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.15.4 Cytovance Biologics Plasmid DNA CDMO Service Product Portfolio
- 12.15.5 Cytovance Biologics Recent Developments
- 12.16 Aldevron
- 12.16.1 Aldevron Company Information
- 12.16.2 Aldevron Business Overview
- 12.16.3 Aldevron Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.16.4 Aldevron Plasmid DNA CDMO Service Product Portfolio
- 12.16.5 Aldevron Recent Developments
- 12.17 Bionova Scientific
- 12.17.1 Bionova Scientific Company Information
- 12.17.2 Bionova Scientific Business Overview
- 12.17.3 Bionova Scientific Revenue in Plasmid DNA CDMO Service Business (2021-2026)
- 12.17.4 Bionova Scientific Plasmid DNA CDMO Service Product Portfolio
- 12.17.5 Bionova Scientific Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst